Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 290 articles: HTML format

Single Articles

April 2021
1. BAUERSACHS J
   The struggle towards a Universal Definition of Heart Failure-how to proceed?
   Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
   PubMed    
   
   
   March 2021
2. CREA F
   Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
   Eur Heart J. 2021;42:1185-1189.
   PubMed    
   
   
   
3. FUKUOKA R, Kawamura A, Kohsaka S
   Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
   Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
   PubMed    
   
   
   
4. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
   The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
   Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. YOUNIS A, Goldenberg I
   Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
   Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
   PubMed    
   
   
   
6. VOLPE M, Patrono C
   The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
   Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
   PubMed    
   
   
   
7. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
   Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
   Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2021
8. VILLRINGER A, Laufs U
   Heart failure, cognition, and brain damage.
   Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
   PubMed    
   
   
   
9. CREA F
   New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
   Eur Heart J. 2021;42:551-554.
   PubMed    
   
   
   
10. 
    Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
    Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
    PubMed    
    
    
    
11. WANG M, Zhou T, Song Y, Li X, et al
    Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
    Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
    PubMed     Abstract available
    
    
    January 2021
12. LOCH A, Koh PS, Manokaran P
    Giant hepatic cyst masquerading as right heart failure.
    Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
    PubMed    
    
    
    
13. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
    Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
    Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. 
    Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2021;42:319.
    PubMed    
    
    
    
15. SMISETH OA, Aalen JM, Skulstad H
    Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
    Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
    PubMed    
    
    
    
16. BAUERSACHS J
    Heart failure drug treatment: the fantastic four.
    Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
    PubMed    
    
    
    
17. HOLT A, Blanche P, Zareini B, Rajan D, et al
    Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
    Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
    PubMed     Abstract available
    
    
    
18. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
    Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
    PubMed     Abstract available
    
    
    
20. CREA F
    Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
    Eur Heart J. 2021;42:139-142.
    PubMed    
    
    
    
21. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
    The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
    Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
    PubMed    
    
    
    December 2020
22. 
    Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
    PubMed    
    
    
    
23. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
    Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. BAKER AH, Giacca M
    Antagonism of miRNA in heart failure: first evidence in human.
    Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
    PubMed    
    
    
    
25. ROY R, Koch WJ
    Adding another GRK to the fire of heart failure.
    Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
    PubMed    
    
    
    November 2020
26. PITT B, Byrd JB
    Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
    Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
    PubMed    
    
    
    
27. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
    Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
    Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
    Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
    Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
    The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
    Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. ALFONSO F
    Heart Failure 2019.
    Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
    PubMed    
    
    
    
31. TAUBEL J, Hauke W, Rump S, Viereck J, et al
    Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2020
32. 
    Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
    Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
    PubMed    
    
    
    
33. BATKAI S, Genschel C, Viereck J, Rump S, et al
    CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. CREA F
    The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
    Eur Heart J. 2020;41:3769-3773.
    PubMed    
    
    
    
35. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
    Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
    Eur Heart J. 2020;41:3863-3864.
    PubMed    
    
    
    
36. LIUZZO G, Patrono C
    EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
    Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
    PubMed    
    
    
    September 2020
37. CREA F
    Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Eur Heart J. 2020;41:3379-3383.
    PubMed    
    
    
    
38. 
    Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure? [Eur Heart J 2020;41: 2411].
    Eur Heart J. 2020 Sep 15. pii: 5906090. doi: 10.1093.
    PubMed    
    
    
    
39. BUTLER J, Zannad F, Filippatos G, Anker SD, et al
    Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
    Eur Heart J. 2020 Sep 15. pii: 5906091. doi: 10.1093.
    PubMed    
    
    
    
40. SAVARESE G, Cosentino F
    The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
    Eur Heart J. 2020 Sep 9. pii: 5903162. doi: 10.1093.
    PubMed    
    
    
    August 2020
41. SERENELLI M, Bohm M, Inzucchi SE, Kober L, et al
    Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
    Eur Heart J. 2020 Aug 21. pii: 5895186. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2020
42. FIGLIOZZI S, Rizzo S, De Gaspari M, Tarantini G, et al
    End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
    Eur Heart J. 2020 Jul 29. pii: 5877566. doi: 10.1093.
    PubMed    
    
    
    
43. 
    Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning.
    Eur Heart J. 2020 Jul 25. pii: 5876171. doi: 10.1093.
    PubMed    
    
    
    
44. ESCANED J, Lerman LO
    Coronary microcirculation and hypertensive heart failure.
    Eur Heart J. 2020;41:2376-2378.
    PubMed    
    
    
    
45. LUSCHER TF
    How to slice the pie: heart failure subgroups and their clinical meaning.
    Eur Heart J. 2020;41:2339-2343.
    PubMed    
    
    
    
46. SCHMIDT IM, Verma A, Waikar SS
    Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
    Eur Heart J. 2020;41:3097-3098.
    PubMed    
    
    
    June 2020
47. KARASON K, Jamaly S
    Heart failure development in obesity: mechanistic pathways.
    Eur Heart J. 2020 Jun 18. pii: 5859181. doi: 10.1093.
    PubMed    
    
    
    
48. ZHOU Y, Liu F, Nie J
    Does hypoperfusion outperformed blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2020 Jun 18. pii: 5859700. doi: 10.1093.
    PubMed    
    
    
    
49. BOCCHINO PP, Angelini F, Frea S
    Intravenous vasodilators in acute heart failure patients with low basic blood pressure: may the benefit come from targeting perfusion rather than pressure?
    Eur Heart J. 2020 Jun 18. pii: 5859697. doi: 10.1093.
    PubMed    
    
    
    
50. KIM J, Kang D, Park H, Kang M, et al
    Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
    Eur Heart J. 2020 Jun 15. pii: 5857797. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. ANKER SD, Butler J, Khan MS, Abraham WT, et al
    Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2020 Jun 4. pii: 5851435. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. CULEBRAS E, Hernandez F
    ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
    Eur Heart J. 2020;41:3095.
    PubMed    
    
    
    May 2020
53. PACKER M
    Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
    Eur Heart J. 2020 May 27. pii: 5847945. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. SAMA IE, Ravera A, Santema BT, van Goor H, et al
    Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
    Eur Heart J. 2020;41:1810-1817.
    PubMed     Abstract available
    
    
    
55. OUDIT GY, Pfeffer MA
    Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19.
    Eur Heart J. 2020;41:1818-1820.
    PubMed    
    
    
    
56. INCIARDI RM, Adamo M, Lupi L, Cani DS, et al
    Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.
    Eur Heart J. 2020;41:1821-1829.
    PubMed     Abstract available
    
    
    
57. THUM T
    SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?
    Eur Heart J. 2020 May 8. pii: 5834515. doi: 10.1093.
    PubMed    
    
    
    
58. OZKAN J
    Trying times for heart failure trials during the COVID-19 pandemic.
    Eur Heart J. 2020;41:1715.
    PubMed    
    
    
    
59. LUSCHER TF
    Cardio-oncology and the future of heart failure.
    Eur Heart J. 2020;41:1709-1712.
    PubMed    
    
    
    
60. PITT B
    Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure.
    Eur Heart J. 2020;41:1615-1617.
    PubMed    
    
    
    
61. MILLER VM
    Universality of sex differences in cardiovascular outcomes: where do we go from here?
    Eur Heart J. 2020;41:1697-1699.
    PubMed    
    
    
    April 2020
62. PACKER M
    Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
    Eur Heart J. 2020 Apr 29. pii: 5827051. doi: 10.1093.
    PubMed    
    
    
    
63. BOHM M, Bewarder Y, Kindermann I
    Ejection fraction in heart failure revisited- where does the evidence start?
    Eur Heart J. 2020 Apr 29. pii: 5827050. doi: 10.1093.
    PubMed    
    
    
    
64. BARTKO PE, Hulsmann M, Hung J, Pavo N, et al
    Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction.
    Eur Heart J. 2020 Apr 29. pii: 5827049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
65. BAYES-GENIS A, Liu PP, Lanfear DE, de Boer RA, et al
    Omics phenotyping in heart failure: the next frontier.
    Eur Heart J. 2020 Apr 26. pii: 5825477. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. TAHARA A, Tahara N, Maeda-Ogata S, Bekki M, et al
    Brown adipose tissue activation in severe heart failure.
    Eur Heart J. 2020 Apr 24. pii: 5824912. doi: 10.1093.
    PubMed    
    
    
    
67. LUSCHER TF
    Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
    Eur Heart J. 2020;41:1311-1314.
    PubMed    
    
    
    March 2020
68. LAM CSP, Voors AA, Piotr P, McMurray JJV, et al
    Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction.
    Eur Heart J. 2020 Mar 30. pii: 5813810. doi: 10.1093.
    PubMed    
    
    
    
69. VADUGANATHAN M, Jhund PS, Claggett BL, Packer M, et al
    A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
    Eur Heart J. 2020 Mar 28. pii: 5813082. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. ZHOU W, Brown JM, Bajaj NS, Chandra A, et al
    Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.
    Eur Heart J. 2020 Mar 28. pii: 5813079. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. DOCHERTY KF, Jhund PS, Inzucchi SE, Kober L, et al
    Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
    Eur Heart J. 2020 Mar 28. pii: 5813081. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. VAN DER LINGEN ACJ, Allaart CP
    The role of implantable cardioverter-defibrillators in New York Heart Class I heart failure patients: do not abandon the asymptomatic just yet.
    Eur Heart J. 2020 Mar 25. pii: 5811615. doi: 10.1093.
    PubMed    
    
    
    
73. GOLDENBERG I, Huang DT, Nielsen JC
    The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
    Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
    PubMed    
    
    
    
74. LUSCHER TF
    Ejection fraction to classify heart failure: are we using the right thing?
    Eur Heart J. 2020;41:1219-1222.
    PubMed    
    
    
    
75. MOTIEJUNAITE J, Akiyama E, Cohen-Solal A, Maggioni AP, et al
    The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.
    Eur Heart J. 2020 Mar 3. pii: 5775572. doi: 10.1093.
    PubMed     Abstract available
    
    
    
76. SLIWA K
    Heart failure can affect everyone: the ESC Geoffrey Rose lecture.
    Eur Heart J. 2020 Mar 2. pii: 5771280. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. BOHM M, Ferreira JP, Mahfoud F, Duarte K, et al
    Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.
    Eur Heart J. 2020 Mar 2. pii: 5771273. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
    The muddy waters of the J-curve and coronary revascularization.
    Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
    PubMed    
    
    
    February 2020
79. JAMALYAN S
    Surgical obesity treatment and the risk of heart failure: the possible mechanisms of interaction and diagnostic accuracy.
    Eur Heart J. 2020 Feb 24. pii: 5753975. doi: 10.1093.
    PubMed    
    
    
    
80. AZAR RR, Abdelmassih T
    Innovation in Heart Failure: from Pills to Devices.
    Eur Heart J. 2020;41:906-907.
    PubMed    
    
    
    
81. VAN WOERDEN G, van Veldhuisen SL, Rienstra M
    Incident heart failure risk after bariatric surgery: the role of epicardial fat.
    Eur Heart J. 2020 Feb 20. pii: 5741377. doi: 10.1093.
    PubMed    
    
    
    January 2020
82. ZHOU Y, Wen J, Nie J
    How much can acute heart failure patients with low basic blood pressure (systolic blood pressure 90-100 mmHg) benefit from the use of vasodilators?
    Eur Heart J. 2020 Jan 10. pii: 5700445. doi: 10.1093.
    PubMed    
    
    
    
83. CLELAND JGF, Lyon AR, McDonagh T, McMurray JJV, et al
    The year in cardiology: heart failure.
    Eur Heart J. 2020 Jan 6. pii: 5694316. doi: 10.1093.
    PubMed    
    
    
    
84. MCMURRAY JJV, Solomon SD, Docherty KF, Jhund PS, et al
    The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
    Eur Heart J. 2020 Jan 3. pii: 5695523. doi: 10.1093.
    PubMed    
    
    
    December 2019
85. COHEN-SOLAL A
    Iron deficiency in heart failure: why so frequent and which mechanisms?
    Eur Heart J. 2019 Dec 20. pii: 5682455. doi: 10.1093.
    PubMed    
    
    
    
86. SCHOU M, Kober L
    Sudden death in heart failure: do we understand what we observe?
    Eur Heart J. 2019 Dec 10. pii: 5671749. doi: 10.1093.
    PubMed    
    
    
    
87. LAM CSP, Arnott C, Beale AL, Chandramouli C, et al
    Sex differences in heart failure.
    Eur Heart J. 2019 Dec 4. pii: 5652224. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2019
88. BARRA S, Providencia R, Narayanan K, Boveda S, et al
    Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.
    Eur Heart J. 2019 Nov 21. pii: 5637310. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. LUSCHER TF
    Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
    Eur Heart J. 2019;40:3579-3582.
    PubMed    
    
    
    
90. OMLAND T
    Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction?
    Eur Heart J. 2019 Nov 4. pii: 5612120. doi: 10.1093.
    PubMed    
    
    
    October 2019
91. NG ACT, Bax JJ
    Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Oct 25. pii: 5607286. doi: 10.1093.
    PubMed    
    
    
    
92. HONARBAKHSH S, Prabhu S, Hunter RJ
    With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?
    Eur Heart J. 2019 Oct 22. pii: 5602553. doi: 10.1093.
    PubMed    
    
    
    
93. REDDY YNV, Obokata M, Wiley B, Koepp KE, et al
    The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Oct 14. pii: 5586988. doi: 10.1093.
    PubMed     Abstract available
    
    
    
94. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure: it's not all about Starling my darling.
    Eur Heart J. 2019 Oct 3. pii: 5580540. doi: 10.1093.
    PubMed    
    
    
    September 2019
95. FELKER GM
    Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure.
    Eur Heart J. 2019 Sep 27. pii: 5575243. doi: 10.1093.
    PubMed    
    
    
    
96. CHATHA SR, Westwood M, Moon JC, Captur G, et al
    New-onset heart failure: free-breathing motion-corrected late gadolinium enhancement rescues the endomyocardial fibrosis diagnosis.
    Eur Heart J. 2019 Sep 27. pii: 5575240. doi: 10.1093.
    PubMed    
    
    
    
97. VAN DER WAL HH, Grote Beverborg N, Dickstein K, Anker SD, et al
    Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.
    Eur Heart J. 2019 Sep 26. pii: 5574384. doi: 10.1093.
    PubMed     Abstract available
    
    
    
98. MARTIN AC, Hemery Y, Godier A
    Comment to "The year in cardiology 2018: heart failure".
    Eur Heart J. 2019 Sep 18. pii: 5571447. doi: 10.1093.
    PubMed    
    
    
    
99. OBOKATA M, Kane GC, Reddy YNV, Melenovsky V, et al
    The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Sep 12. pii: 5568303. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2019
100. PIESKE B, Tschope C, de Boer RA, Fraser AG, et al
     How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2019 Aug 31. pii: 5557740. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. TAYAL B, Fruelund P, Sogaard P, Riahi S, et al
     Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.
     Eur Heart J. 2019 Aug 26. pii: 5554632. doi: 10.1093.
     PubMed     Abstract available
     
     
     
102. ROHDE LE, Rover MM, Figueiredo Neto JA, Danzmann LC, et al
     Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
     Eur Heart J. 2019 Aug 19. pii: 5551388. doi: 10.1093.
     PubMed     Abstract available
     
     
     
103. MICHOU E, Fahrni G, Mueller C
     Quantifying heart failure using natriuretic peptides may help the HEART team in decision-making.
     Eur Heart J. 2019 Aug 19. pii: 5551384. doi: 10.1093.
     PubMed    
     
     
     
104. PACKER M
     What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?
     Eur Heart J. 2019 Aug 7. pii: 5544750. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. MCINTYRE WF, Connolly SJ, Wang J, Masiero S, et al
     Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
     Eur Heart J. 2019 Aug 4. pii: 5543556. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. MAGGIONI AP, Andreotti F
     Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?
     Eur Heart J. 2019 Aug 1. pii: 5542639. doi: 10.1093.
     PubMed    
     
     
     July 2019
107. HOFMANN C, Volkers M, Katus HA
     Targeting coagulation in heart failure with preserved ejection fraction and cardiac fibrosis.
     Eur Heart J. 2019 Jul 19. pii: 5536327. doi: 10.1093.
     PubMed    
     
     
     
108. CHEN S, Purerfellner H, Meyer C, Acou WJ, et al
     Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data.
     Eur Heart J. 2019 Jul 11. pii: 5531275. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. WATSON WD
     Reply to the commentary: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
     Eur Heart J. 2019 Jul 10. pii: 5530696. doi: 10.1093.
     PubMed    
     
     
     
110. GHIMIRE A, Fine N, Ezekowitz JA, Howlett J, et al
     Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study.
     Eur Heart J. 2019;40:2110-2117.
     PubMed     Abstract available
     
     
     June 2019
111. CLELAND JGF, Hindricks G, Petrie M
     The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization.
     Eur Heart J. 2019 Jun 30. pii: 5525356. doi: 10.1093.
     PubMed    
     
     
     
112. HAMMERSLEY D, Halliday BP, Prasad SK
     Can we turn heart failure into heart success by studying myocardial remission?
     Eur Heart J. 2019 Jun 28. pii: 5524810. doi: 10.1093.
     PubMed    
     
     
     
113. MEHRA MR, Vaduganathan M, Fu M, Ferreira JP, et al
     A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
     Eur Heart J. 2019 Jun 25. pii: 5522950. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. REDDY YNV, Borlaug BA, O'Connor CM, Gersh BJ, et al
     Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions.
     Eur Heart J. 2019 Jun 14. pii: 5519089. doi: 10.1093.
     PubMed     Abstract available
     
     
     
115. FINER N
     Weight loss for patients with obesity and heart failure.
     Eur Heart J. 2019 Jun 10. pii: 5513287. doi: 10.1093.
     PubMed    
     
     
     
116. GENTILLE LORENTE DI
     Coconut atrium: a rare entity to cause pulmonary hypertension.
     Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
     PubMed    
     
     
     May 2019
117. PACKER M
     Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.
     Eur Heart J. 2019 May 23. pii: 5497835. doi: 10.1093.
     PubMed    
     
     
     
118. MORROW DA, Velazquez EJ, DeVore AD, Prescott MF, et al
     Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
     Eur Heart J. 2019 May 15. pii: 5489800. doi: 10.1093.
     PubMed     Abstract available
     
     
     
119. JAMALY S, Carlsson L, Peltonen M, Jacobson P, et al
     Surgical obesity treatment and the risk of heart failure.
     Eur Heart J. 2019 May 14. pii: 5489332. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. PACKER M
     Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation.
     Eur Heart J. 2019 May 12. pii: 5488510. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2019
121. SKELIN M, Lucijanic M, Javor E
     The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes.
     Eur Heart J. 2019 Apr 28. pii: 5481181. doi: 10.1093.
     PubMed    
     
     
     
122. BERTERO E, Sequeira V, Heymans S, Maack C, et al
     Response to 'The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes'.
     Eur Heart J. 2019 Apr 28. pii: 5481175. doi: 10.1093.
     PubMed    
     
     
     
123. VON HAEHLING S, Doehner W, Anker SD
     The evolving obesity paradigm story: from heart failure to atrial fibrillation.
     Eur Heart J. 2019 Apr 21. pii: 5476266. doi: 10.1093.
     PubMed    
     
     
     
124. PRAZ F, Grasso C, Taramasso M, Baumbach A, et al
     Mitral regurgitation in heart failure: time for a rethink.
     Eur Heart J. 2019 Apr 21. pii: 5475839. doi: 10.1093.
     PubMed    
     
     
     
125. TRIPOSKIADIS F, Butler J, Abboud FM, Armstrong PW, et al
     The continuous heart failure spectrum: moving beyond an ejection fraction classification.
     Eur Heart J. 2019 Apr 8. pii: 5431175. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2019
126. CLELAND JGF, van Veldhuisen DJ, Ponikowski P
     The year in cardiology 2018: heart failure.
     Eur Heart J. 2019;40:651-661.
     PubMed    
     
     
     
127. VAN DEN BERG MP, Mulder BA, Klaassen SHC, Maass AH, et al
     Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
     Eur Heart J. 2019 Feb 8. pii: 5310346. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. HILFIKER-KLEINER D, Ardehali H, Fischmeister R, Burridge P, et al
     Late onset heart failure after childhood chemotherapy.
     Eur Heart J. 2019 Feb 7. pii: 5309990. doi: 10.1093.
     PubMed    
     
     
     
129. 
     Heart Failure and Sepsis: Cardiologists have developed a new 'risk profile' tool to identify heart failure patients at risk of dying from sepsis. Mark Nicholls reports.
     Eur Heart J. 2019;40:409-410.
     PubMed    
     
     
     January 2019
130. TARAMASSO M, Gavazzoni M, Maisano F
     Is tricuspid regurgitation a prognostic interventional target or is it just an indicator of worst prognosis in heart failure patients?
     Eur Heart J. 2019 Jan 25. pii: 5301478. doi: 10.1093.
     PubMed    
     
     
     
131. GORTER TM, van Veldhuisen DJ, Voors AA
     Rapid right-sided deterioration in heart failure with preserved ejection fraction.
     Eur Heart J. 2019 Jan 4. pii: 5273477. doi: 10.1093.
     PubMed    
     
     
     
132. WOJAKOWSKI W, Baumgartner H
     The year in cardiology 2018: valvular heart disease.
     Eur Heart J. 2019 Jan 2. pii: 5265301. doi: 10.1093.
     PubMed    
     
     
     
133. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
     Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
     Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2018
134. HALLIDAY BP, Pennell DJ
     Prediction and prevention of heart failure in high-risk elderly patients.
     Eur Heart J. 2018 Dec 27. pii: 5263767. doi: 10.1093.
     PubMed    
     
     
     
135. LUSCHER TF
     Personalized approaches to heart failure: age, acute presentation, and comorbidities.
     Eur Heart J. 2018;39:4223-4226.
     PubMed    
     
     
     
136. RICHTER S, Di Biase L, Hindricks G
     Atrial fibrillation ablation in heart failure.
     Eur Heart J. 2018 Dec 14. pii: 5248225. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. TROMP J, Ouwerkerk W, Demissei BG, Anker SD, et al
     Novel endotypes in heart failure: effects on guideline-directed medical therapy.
     Eur Heart J. 2018 Dec 13. pii: 5245844. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. OBOKATA M, Reddy YNV, Melenovsky V, Pislaru S, et al
     Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
     Eur Heart J. 2018 Dec 12. pii: 5240922. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2018
139. TINI G, Olivotto I, Canepa M
     Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues.
     Eur Heart J. 2018 Nov 29. pii: 5219619. doi: 10.1093.
     PubMed    
     
     
     
140. 
     Corrigendum to: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
     Eur Heart J. 2018 Nov 23. pii: 5203433. doi: 10.1093.
     PubMed    
     
     
     
141. 
     Corrigendum to: Heart failure with preserved ejection fraction: from mechanisms to therapies.
     Eur Heart J. 2018 Nov 23. pii: 5203434. doi: 10.1093.
     PubMed    
     
     
     
142. SIONTIS KC, Yao X, Noseworthy PA
     Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?
     Eur Heart J. 2018 Nov 20. pii: 5193438. doi: 10.1093.
     PubMed    
     
     
     
143. NISHIMURA M, Maisel AS
     Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction.
     Eur Heart J. 2018;39:3876-3878.
     PubMed    
     
     
     October 2018
144. BOERSMA LVA
     Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?
     Eur Heart J. 2018 Oct 25. pii: 5145027. doi: 10.1093.
     PubMed    
     
     
     
145. BEGGS SAS, Jhund PS, McMurray JJV
     Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA.
     Eur Heart J. 2018 Oct 23. pii: 5143981. doi: 10.1093.
     PubMed    
     
     
     
146. SAVARESE G, Dahlstrom U, Vasko P, Pitt B, et al
     Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
     Eur Heart J. 2018 Oct 22. pii: 5142410. doi: 10.1093.
     PubMed     Abstract available
     
     
     
147. WANG N, Fulcher J, Abeysuriya N, McGrady M, et al
     Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.
     Eur Heart J. 2018 Oct 22. pii: 5142409. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. FUDIM M, Ganesh A, Green C, Jones WS, et al
     Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.
     Eur Heart J. 2018 Oct 20. pii: 5135328. doi: 10.1093.
     PubMed    
     
     
     
149. YANG XQ, Xiong T, Wang DX
     The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction.
     Eur Heart J. 2018 Oct 17. pii: 5137111. doi: 10.1093.
     PubMed    
     
     
     
150. BALLIGAND JL
     Response to 'The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction'.
     Eur Heart J. 2018 Oct 17. pii: 5137137. doi: 10.1093.
     PubMed    
     
     
     
151. PETROVIC J, Boricic I, Petrovic M, Ivanovic B, et al
     Endomyocardial fibrosis and unileaflet mitral valve: a fatal postpartum outcome.
     Eur Heart J. 2018 Oct 17. pii: 5137115. doi: 10.1093.
     PubMed    
     
     
     
152. ZAFRIR B, Lund LH, Laroche C, Ruschitzka F, et al
     Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
     Eur Heart J. 2018 Oct 15. pii: 5133012. doi: 10.1093.
     PubMed     Abstract available
     
     
     
153. MAACK C, Lehrke M, Backs J, Heinzel FR, et al
     Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
     Eur Heart J. 2018 Oct 8. pii: 5123540. doi: 10.1093.
     PubMed    
     
     
     
154. HASIN T, Glikson M, Hasin Y
     The Heart Failure Unit At Shaare Zedek Hospital Medical Center.
     Eur Heart J. 2018;39:3491-3492.
     PubMed    
     
     
     
155. HASIN T, Zalut T, Hasin Y
     Managing the Patient with Heart Failure in the Emergency Department.
     Eur Heart J. 2018;39:3493-3495.
     PubMed    
     
     
     September 2018
156. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
     Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014.
     Eur Heart J. 2018 Sep 19. pii: 5103432. doi: 10.1093.
     PubMed     Abstract available
     
     
     
157. ESHAK N, Abdelnaby M, Shehata H, Ziada K, et al
     A case of fibrosing mediastinitis complicated by pulmonary hypertension and right-sided heart failure.
     Eur Heart J. 2018 Sep 7. pii: 5092489. doi: 10.1093.
     PubMed    
     
     
     August 2018
158. SHAH SJ, Lam CSP, Svedlund S, Saraste A, et al
     Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
     Eur Heart J. 2018 Aug 27. pii: 5077831. doi: 10.1093.
     PubMed     Abstract available
     
     
     
159. GUSTAFSSON F, Shaw S, Lavee J, Saeed D, et al
     Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry.
     Eur Heart J. 2018 Aug 27. pii: 5084900. doi: 10.1093.
     PubMed     Abstract available
     
     
     
160. WEI J, Nelson MD, Sharif B, Shufelt C, et al
     Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines.
     Eur Heart J. 2018 Aug 27. pii: 5079249. doi: 10.1093.
     PubMed    
     
     
     
161. SANTEMA BT, Kloosterman M, Van Gelder IC, Mordi I, et al
     Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
     Eur Heart J. 2018 Aug 22. pii: 5077588. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. CHAGGAR P, Squire I, Kalra PR
     British Society of Heart Failure.
     Eur Heart J. 2018;39:2773-2774.
     PubMed    
     
     
     
163. LUSCHER TF
     Heart failure with preserved ejection fraction: unravelling an enigma.
     Eur Heart J. 2018;39:2763-2766.
     PubMed    
     
     
     
164. AMSTEIN R
     The New Postgraduate Course in Heart Failure.
     Eur Heart J. 2018;39:2775-2777.
     PubMed    
     
     
     
165. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
     Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
     Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
     PubMed     Abstract available
     
     
     
166. RUSH CJ, Campbell RT, Jhund PS, Petrie MC, et al
     Association is not causation: treatment effects cannot be estimated from observational data in heart failure.
     Eur Heart J. 2018 Aug 1. pii: 5063542. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2018
167. TAKAHAMA H, Minamino N, Izumi C
     Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?
     Eur Heart J. 2018 Jul 27. pii: 5060561. doi: 10.1093.
     PubMed    
     
     
     
168. TOPILSKY Y, Inojosa JM, Benfari G, Vaturi O, et al
     Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction.
     Eur Heart J. 2018 Jul 27. pii: 5060565. doi: 10.1093.
     PubMed     Abstract available
     
     
     
169. VAN EMPEL V, Brunner-La Rocca HP
     Helping to understand heart failure with preserved ejection fraction.
     Eur Heart J. 2018 Jul 9. pii: 5050878. doi: 10.1093.
     PubMed    
     
     
     June 2018
170. GORTER TM, Obokata M, Reddy YNV, Melenovsky V, et al
     Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.
     Eur Heart J. 2018 Jun 26. pii: 5045545. doi: 10.1093.
     PubMed     Abstract available
     
     
     
171. WEBER T, Chirinos JA
     Pulsatile arterial haemodynamics in heart failure.
     Eur Heart J. 2018 Jun 26. pii: 5045547. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. PACKER M
     Questioning the obvious: does dyspnoea really matter in heart failure?
     Eur Heart J. 2018 Jun 22. pii: 5043114. doi: 10.1093.
     PubMed    
     
     
     
173. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
     Heart failure with preserved ejection fraction: from mechanisms to therapies.
     Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2018
174. LUSCHER TF
     Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
     Eur Heart J. 2018;39:1749-1753.
     PubMed    
     
     
     
175. ANGERMANN CE, Frantz S, Maack C
     The Comprehensive Heart Failure Centre in Wurzburg, Germany.
     Eur Heart J. 2018;39:1757-1760.
     PubMed    
     
     
     
176. SWOBODA PP, Plein S
     Heart failure in Diabetic patients.
     Eur Heart J. 2018;39:1755-1757.
     PubMed    
     
     
     
177. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
     Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
     Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
     PubMed     Abstract available
     
     
     March 2018
178. VADUGANATHAN M, Solomon SD
     Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
     Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
     PubMed    
     
     
     
179. FONSECA C
     A Heart Failure Clinic.
     Eur Heart J. 2018;39:826-828.
     PubMed    
     
     
     
180. BEGGS S, Gardner R
     Thirty years of heart failure.
     Eur Heart J. 2018;39:824-826.
     PubMed    
     
     
     February 2018
181. YAMAMOTO M, Seo Y, Ishizu T, Aonuma K, et al
     Reversible aortic valve stenosis with Loffler endocarditis.
     Eur Heart J. 2018 Feb 26. pii: 4911114. doi: 10.1093.
     PubMed    
     
     
     
182. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
     Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
     Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
     Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
     Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2018
184. LAM CSP, Gamble GD, Ling LH, Sim D, et al
     Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
     Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
     PubMed     Abstract available
     
     
     
185. MEHLUM MH, Liestol K, Kjeldsen SE, Julius S, et al
     Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
     Eur Heart J. 2018 Jan 20. pii: 4815726. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. NELSON MD, Wei J, Bairey Merz CN
     Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
     Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
     PubMed    
     
     
     
187. HEINZMANN D, Seizer P
     Mitochondria in heart failure: EMID-sign.
     Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
     PubMed    
     
     
     
188. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
     The year in cardiology 2017: heart failure.
     Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
     PubMed    
     
     
     
189. LUSCHER TF
     Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
     Eur Heart J. 2018;39:1-4.
     PubMed    
     
     
     
190. PACKER M
     The Future Treatment of Heart Failure?
     Eur Heart J. 2018;39:5-7.
     PubMed    
     
     
     December 2017
191. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
     Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
     Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
     PubMed     Abstract available
     
     
     
192. BERMEJO J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, et al
     Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
     Eur Heart J. 2017 Dec 21. pii: 4769387. doi: 10.1093.
     PubMed     Abstract available
     
     
     
193. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
     The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
     Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
     PubMed     Abstract available
     
     
     
194. WILCOX JE, Mann DL
     Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
     Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
     PubMed    
     
     
     November 2017
195. MASIP J, Peacock WF, Price S, Cullen L, et al
     Indications and practical approach to non-invasive ventilation in acute heart failure.
     Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
     PubMed     Abstract available
     
     
     
196. GRASSI G, Mancia G
     'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
     Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
     PubMed    
     
     
     
197. NICHOLLS M
     Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
     Eur Heart J. 2017;38:3249-3250.
     PubMed    
     
     
     
198. ROSANO GMC
     HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
     Eur Heart J. 2017;38:3042-3043.
     PubMed    
     
     
     
199. TOFIELD A
     Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
     Eur Heart J. 2017;38:3041.
     PubMed    
     
     
     October 2017
200. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
     Retinal microvascular dysfunction in heart failure.
     Eur Heart J. 2017 Oct 21. doi: 10.1093.
     PubMed     Abstract available
     
     
     
201. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
     Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
     Eur Heart J. 2017 Oct 10. doi: 10.1093.
     PubMed     Abstract available
     
     
     
202. LUSCHER TF
     Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
     Eur Heart J. 2017;38:2857-2859.
     PubMed    
     
     
     
203. BLANTON RM
     What can haemodynamic profiles teach us about heart failure in the paediatric population?
     Eur Heart J. 2017;38:2910-2911.
     PubMed    
     
     
     
204. PITT B, Rossignol P
     Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
     Eur Heart J. 2017;38:2897-2899.
     PubMed    
     
     
     
205. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
     Haemodynamic profiles of children with end-stage heart failure.
     Eur Heart J. 2017;38:2900-2909.
     PubMed     Abstract available
     
     
     
206. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
     Associations of serum potassium levels with mortality in chronic heart failure patients.
     Eur Heart J. 2017;38:2890-2896.
     PubMed     Abstract available
     
     
     September 2017
207. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
     The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
     Eur Heart J. 2017 Sep 27. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2017
208. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
     Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
     Eur Heart J. 2017 Aug 29. doi: 10.1093.
     PubMed     Abstract available
     
     
     
209. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
     Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
     Eur Heart J. 2017 Aug 28. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. LUSCHER TF
     Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
     Eur Heart J. 2017;38:2315-2317.
     PubMed    
     
     
     
211. DE BOER RA, Meems LMG, van Veldhuisen DJ
     Vitamin D supplementation in heart failure: case closed?
     Eur Heart J. 2017;38:2287-2289.
     PubMed    
     
     
     July 2017
212. DE WAHA S, Patel MR, Granger CB, Ohman EM, et al
     Relationship between microvascular obstruction and adverse events following primary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.
     Eur Heart J. 2017 Jul 28. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
     Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
     Eur Heart J. 2017 Jul 25. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2017
214. LUSCHER TF
     Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
     Eur Heart J. 2017;38:1857-1860.
     PubMed    
     
     
     
215. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
     Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
     Eur Heart J. 2017;38:1784-1786.
     PubMed    
     
     
     
216. CHATTERJEE NA, Singh JP
     Making sense of remote monitoring studies in heart failure.
     Eur Heart J. 2017 Jun 13. doi: 10.1093.
     PubMed    
     
     
     
217. SUGIHARA S, Burnett JC Jr
     BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
     Eur Heart J. 2017 Jun 1. doi: 10.1093.
     PubMed    
     
     
     May 2017
218. MORGAN JM, Kitt S, Gill J, McComb JM, et al
     Remote management of heart failure using implantable electronic devices.
     Eur Heart J. 2017 May 27. doi: 10.1093.
     PubMed     Abstract available
     
     
     
219. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
     Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
     Eur Heart J. 2017 May 20. doi: 10.1093.
     PubMed     Abstract available
     
     
     
220. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
     Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
     Eur Heart J. 2017 May 12. doi: 10.1093.
     PubMed     Abstract available
     
     
     
221. SCHUPKE S, Mehilli J
     Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
     Eur Heart J. 2017 May 5. doi: 10.1093.
     PubMed    
     
     
     April 2017
222. PANG PS, Butler J, Collins SP, Cotter G, et al
     Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
     Eur Heart J. 2017 Apr 27. doi: 10.1093.
     PubMed     Abstract available
     
     
     
223. BORLAUG BA, Obokata M
     Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
     Eur Heart J. 2017 Apr 17. doi: 10.1093.
     PubMed    
     
     
     
224. LUSCHER TF
     From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
     Eur Heart J. 2017;38:1087-1090.
     PubMed    
     
     
     
225. CLELAND JGF, Mueller C
     What can we learn from SOCRATES: more questions than answers?
     Eur Heart J. 2017;38:1128-1131.
     PubMed    
     
     
     
226. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
     Taxonomy of segmental myocardial systolic dysfunction.
     Eur Heart J. 2017;38:942-954.
     PubMed     Abstract available
     
     
     March 2017
227. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
     Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
     Eur Heart J. 2017 Mar 22. doi: 10.1093.
     PubMed     Abstract available
     
     
     
228. MCCULLOUGH PA, Rios A, Smith B
     Dialysis fistulas and heart failure.
     Eur Heart J. 2017 Mar 17. doi: 10.1093.
     PubMed    
     
     
     
229. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
     Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
     Eur Heart J. 2017 Mar 11. doi: 10.1093.
     PubMed     Abstract available
     
     
     
230. LUSCHER TF
     Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
     Eur Heart J. 2017;38:693-696.
     PubMed    
     
     
     
231. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
     Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
     Eur Heart J. 2017;38:742-750.
     PubMed     Abstract available
     
     
     
232. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
     Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
     Eur Heart J. 2017;38:720-726.
     PubMed     Abstract available
     
     
     
233. STEPHAN VON BARDELEBEN R, Tamm A, Emrich T, Munzel T, et al
     Percutaneous transvenous direct annuloplasty of a human tricuspid valve using the Valtech Cardioband.
     Eur Heart J. 2017;38:690.
     PubMed    
     
     
     February 2017
234. 
     Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
     Eur Heart J. 2017 Feb 28. doi: 10.1093.
     PubMed    
     
     
     
235. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
     Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
     Eur Heart J. 2017 Feb 23. doi: 10.1093.
     PubMed     Abstract available
     
     
     
236. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
     The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
     Eur Heart J. 2017 Feb 15. doi: 10.1093.
     PubMed    
     
     
     
237. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
     Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
     Eur Heart J. 2017 Feb 15. doi: 10.1093.
     PubMed    
     
     
     
238. BOHM M, Young R, Jhund PS, Solomon SD, et al
     Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
     Eur Heart J. 2017 Feb 1. doi: 10.1093.
     PubMed    
     
     
     
239. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
     Agents with vasodilator properties in acute heart failure.
     Eur Heart J. 2017;38:317-325.
     PubMed    
     
     
     
240. LUSCHER TF
     An update on heart failure: from experimental findings to clinical trials.
     Eur Heart J. 2017;38:305-307.
     PubMed    
     
     
     
241. TOFIELD A
     Teenage weight and risk for adult heart failure.
     Eur Heart J. 2017;38:311-312.
     PubMed    
     
     
     
242. TOFIELD A
     End of the road for aliskiren in heart failure.
     Eur Heart J. 2017;38:312-313.
     PubMed    
     
     
     
243. 
     Professor Jay Cohn a pioneer in heart failure.
     Eur Heart J. 2017;38:308-309.
     PubMed    
     
     
     
244. HARPER AR, Cowie MR
     Remote monitoring for heart failure: the story moves on.
     Eur Heart J. 2017;38:310-311.
     PubMed    
     
     
     January 2017
245. BRUNO RM, Taddei S
     Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
     Eur Heart J. 2017 Jan 30. doi: 10.1093.
     PubMed    
     
     
     
246. HORCKMANS M, Ring L, Duchene J, Santovito D, et al
     Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.
     Eur Heart J. 2017;38:187-197.
     PubMed    
     
     
     
247. LANDIN AM, Hare JM
     The quest for a successful cell-based therapeutic approach for heart failure.
     Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
     PubMed    
     
     
     
248. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
     Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
     Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
     PubMed    
     
     
     
249. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
     Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
     Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
     PubMed     Abstract available
     
     
     
250. MAGGIONI AP, Ruschitzka F
     The year in cardiology 2016: heart failure.
     Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
     PubMed    
     
     
     December 2016
251. MAISEL AS, Di Somma S
     Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
     Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
     PubMed    
     
     
     
252. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
     Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
     Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
     PubMed    
     
     
     
253. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
     Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
     Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
     PubMed     Abstract available
     
     
     
254. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
     Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
     Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
     PubMed    
     
     
     
255. MINOIA C, Paolillo S
     Two weeks at Harvard, for two European heart failure trainees.
     Eur Heart J. 2016;37:3553-3554.
     PubMed    
     
     
     
256. PAOLILLO S
     The ESC Heart Failure Association postgraduate course in heart failure.
     Eur Heart J. 2016;37:3551-3552.
     PubMed    
     
     
     November 2016
257. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
     Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
     Eur Heart J. 2016.
     PubMed    
     
     
     
258. 
     What the Heart Failure Congress means to the Heart Failure Association.
     Eur Heart J. 2016;37:3124-3126.
     PubMed    
     
     
     
259. 
     First European advice launched for acute heart failure.
     Eur Heart J. 2016;37:3123-3124.
     PubMed    
     
     
     
260. 
     What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
     Eur Heart J. 2016;37:3121-3122.
     PubMed    
     
     
     October 2016
261. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
     The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
     Eur Heart J. 2016.
     PubMed    
     
     
     
262. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
     How robust are clinical trials in heart failure?
     Eur Heart J. 2016.
     PubMed     Abstract available
     
     
     September 2016
263. JORGE C, Hiltrop N, Desmet W
     Heart failure with preserved ejection fraction: blame the veins....
     Eur Heart J. 2016.
     PubMed    
     
     
     
264. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
     Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
     Eur Heart J. 2016.
     PubMed     Abstract available
     
     
     
265. JHUND PS
     Obesity and heart failure: when 'epidemics' collide.
     Eur Heart J. 2016 Sep 22. doi: 10.1093.
     PubMed    
     
     
     
266. FRADLEY MG
     The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
     Eur Heart J. 2016;37:2740-2742.
     PubMed    
     
     
     
267. ZHABYEYEV P, Oudit GY
     Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
     Eur Heart J. 2016.
     PubMed    
     
     
     
268. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
     Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
     Eur Heart J. 2016.
     PubMed    
     
     
     
269. 
     The Acute Heart Failure Academy.
     Eur Heart J. 2016;37:2568-9.
     PubMed    
     
     
     
270. LUSCHER TF
     From heart failure to transplantation: genes, miRNAs, and biomarkers.
     Eur Heart J. 2016;37:2561-3.
     PubMed    
     
     
     August 2016
271. LUSCHER TF
     Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders.
     Eur Heart J. 2016;37:2443-5.
     PubMed    
     
     
     April 2016
272. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
     Myocardial strain imaging: how useful is it in clinical decision making?
     Eur Heart J. 2016;37:1196-207.
     PubMed     Abstract available
     
     
     
273. PATIL NP, Weymann A, Popov AF, Simon AR, et al
     Chest X-ray in cardiac illness: a tale of four decades.
     Eur Heart J. 2016;37:1243.
     PubMed    
     
     
     
274. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
     Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
     Eur Heart J. 2016;37:1015-23.
     PubMed    
     
     
     March 2016
275. LUSCHER TF
     Update on hypertension: target blood pressure, comorbidities, and outcome.
     Eur Heart J. 2016;37:921-3.
     PubMed    
     
     
     February 2016
276. LOCH A, Geh DJ, Veriah RS
     Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
     Eur Heart J. 2016;37:702.
     PubMed    
     
     
     
277. DWECK M, Chin C
     CardioPulse: Settling scores with a failing heart.
     Eur Heart J. 2016;37:433-4.
     PubMed    
     
     
     
278. WESTENBRINK BD, van Laake LW, Brugts JJ
     CardioPulse: The Postgraduate Course in Heart Failure.
     Eur Heart J. 2016;37:428-9.
     PubMed    
     
     
     
279. DIMARCO A, Mansoubi H, Tanner M
     An unusual cause of left ventricular hypertrophy.
     Eur Heart J. 2016;37:497.
     PubMed    
     
     
     
280. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
     Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
     Eur Heart J. 2016;37:473-83.
     PubMed     Abstract available
     
     
     
281. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
     Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
     Eur Heart J. 2016;37:484-93.
     PubMed     Abstract available
     
     
     January 2016
282. RABER L, Piccolo R
     CardioPulse: Different bleeding scores and which one should we use?
     Eur Heart J. 2016;37:327-31.
     PubMed    
     
     
     
283. NICHOLLS M
     CardioPulse: Cyclosporine to reduce myocardial infarction injury?
     Eur Heart J. 2016;37:210-1.
     PubMed    
     
     
     December 2015
284. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
     Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
     Eur Heart J. 2015.
     PubMed     Abstract available
     
     
     November 2015
285. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
     One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
     Eur Heart J. 2015.
     PubMed     Abstract available
     
     
     August 2015
286. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
     Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
     Eur Heart J. 2015.
     PubMed    
     
     
     
287. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
     Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
     Eur Heart J. 2015.
     PubMed     Abstract available
     
     
     July 2015
288. CORRADO D, Wichter T, Link MS, Hauer R, et al
     Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
     Eur Heart J. 2015.
     PubMed    
     
     
     June 2015
289. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
     Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
     Eur Heart J. 2015.
     PubMed    
     
     
     
290. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
     Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
     Eur Heart J. 2015.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: